

Covid-19 Impact on Global Metabolic Disorder Therapeutics Market Size, Status and Forecast 2020-2026

<https://marketpublishers.com/r/C4EC4E751BEFEN.html>

Date: June 2020

Pages: 125

Price: US\$ 3,900.00 (Single User License)

ID: C4EC4E751BEFEN

Abstracts

Increasing demand for one-time therapies for metabolic disorders and rising prevalence of lifestyle diseases are the key factors that are expected to boost the growth of this market.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Metabolic Disorder Therapeutics market in 2020.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

This report also analyses the impact of Coronavirus COVID-19 on the Metabolic Disorder Therapeutics industry.

Based on our recent survey, we have several different scenarios about the Metabolic Disorder Therapeutics YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US\$ 45990 million in 2019. The market size of Metabolic Disorder Therapeutics will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Metabolic Disorder

Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Metabolic Disorder Therapeutics market in terms of revenue.

Players, stakeholders, and other participants in the global Metabolic Disorder Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.

Regional and Country-level Analysis

The report offers an exhaustive geographical analysis of the global Metabolic Disorder Therapeutics market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.

Competition Analysis

In the competitive analysis section of the report, leading as well as prominent players of the global Metabolic Disorder Therapeutics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Metabolic Disorder Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Metabolic Disorder Therapeutics market.

The following players are covered in this report:

Novo Nordisk A/S

Sanofi S.A.

Boehringer Ingelheim GmbH

Eli Lilly and Company

Merck KgaA

Amgen, Inc.

AstraZeneca PLC

Actelion Pharmaceuticals Ltd.

Shire PLC

AbbVie, Inc.

Biocon Ltd.

BioMarin Pharmaceutical, Inc.

Bristol-Myers Squibb Company

Cipla, Inc.

CymaBay Therapeutics, Inc.

Metabolic Disorder Therapeutics Breakdown Data by Type

Lysosomal Storage Diseases

Diabetes

Obesity

Inherited Metabolic Disorders

Hypercholesterolemia

Metabolic Disorder Therapeutics Breakdown Data by Application

Oral

Parenteral

Others

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Metabolic Disorder Therapeutics Revenue

1.4 Market Analysis by Type

1.4.1 Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type: 2020 VS 2026

1.4.2 Lysosomal Storage Diseases

1.4.3 Diabetes

1.4.4 Obesity

1.4.5 Inherited Metabolic Disorders

1.4.6 Hypercholesterolemia

1.5 Market by Application

1.5.1 Global Metabolic Disorder Therapeutics Market Share by Application: 2020 VS 2026

1.5.2 Oral

1.5.3 Parenteral

1.5.4 Others

1.6 Coronavirus Disease 2019 (Covid-19): Metabolic Disorder Therapeutics Industry Impact

1.6.1 How the Covid-19 is Affecting the Metabolic Disorder Therapeutics Industry

1.6.1.1 Metabolic Disorder Therapeutics Business Impact Assessment - Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products

1.6.2 Market Trends and Metabolic Disorder Therapeutics Potential Opportunities in the COVID-19 Landscape

1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for Metabolic Disorder Therapeutics Players to Combat Covid-19

Impact

1.7 Study Objectives

1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Metabolic Disorder Therapeutics Market Perspective (2015-2026)

2.2 Metabolic Disorder Therapeutics Growth Trends by Regions

2.2.1 Metabolic Disorder Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026

2.2.2 Metabolic Disorder Therapeutics Historic Market Share by Regions (2015-2020)

2.2.3 Metabolic Disorder Therapeutics Forecasted Market Size by Regions (2021-2026)

2.3 Industry Trends and Growth Strategy

2.3.1 Market Top Trends

2.3.2 Market Drivers

2.3.3 Market Challenges

2.3.4 Porter's Five Forces Analysis

2.3.5 Metabolic Disorder Therapeutics Market Growth Strategy

2.3.6 Primary Interviews with Key Metabolic Disorder Therapeutics Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Metabolic Disorder Therapeutics Players by Market Size

3.1.1 Global Top Metabolic Disorder Therapeutics Players by Revenue (2015-2020)

3.1.2 Global Metabolic Disorder Therapeutics Revenue Market Share by Players (2015-2020)

3.1.3 Global Metabolic Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

3.2 Global Metabolic Disorder Therapeutics Market Concentration Ratio

3.2.1 Global Metabolic Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)

3.2.2 Global Top 10 and Top 5 Companies by Metabolic Disorder Therapeutics Revenue in 2019

3.3 Metabolic Disorder Therapeutics Key Players Head office and Area Served

3.4 Key Players Metabolic Disorder Therapeutics Product Solution and Service

3.5 Date of Enter into Metabolic Disorder Therapeutics Market

3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Metabolic Disorder Therapeutics Historic Market Size by Type (2015-2020)

4.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Type (2021-2026)

5 METABOLIC DISORDER THERAPEUTICS BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Metabolic Disorder Therapeutics Market Size by Application (2015-2020)

5.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Metabolic Disorder Therapeutics Market Size (2015-2020)

6.2 Metabolic Disorder Therapeutics Key Players in North America (2019-2020)

6.3 North America Metabolic Disorder Therapeutics Market Size by Type (2015-2020)

6.4 North America Metabolic Disorder Therapeutics Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Metabolic Disorder Therapeutics Market Size (2015-2020)

7.2 Metabolic Disorder Therapeutics Key Players in Europe (2019-2020)

7.3 Europe Metabolic Disorder Therapeutics Market Size by Type (2015-2020)

7.4 Europe Metabolic Disorder Therapeutics Market Size by Application (2015-2020)

8 CHINA

8.1 China Metabolic Disorder Therapeutics Market Size (2015-2020)

8.2 Metabolic Disorder Therapeutics Key Players in China (2019-2020)

8.3 China Metabolic Disorder Therapeutics Market Size by Type (2015-2020)

8.4 China Metabolic Disorder Therapeutics Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Metabolic Disorder Therapeutics Market Size (2015-2020)

9.2 Metabolic Disorder Therapeutics Key Players in Japan (2019-2020)

9.3 Japan Metabolic Disorder Therapeutics Market Size by Type (2015-2020)

9.4 Japan Metabolic Disorder Therapeutics Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Metabolic Disorder Therapeutics Market Size (2015-2020)

- 10.2 Metabolic Disorder Therapeutics Key Players in Southeast Asia (2019-2020)
- 10.3 Southeast Asia Metabolic Disorder Therapeutics Market Size by Type (2015-2020)
- 10.4 Southeast Asia Metabolic Disorder Therapeutics Market Size by Application (2015-2020)

11 INDIA

- 11.1 India Metabolic Disorder Therapeutics Market Size (2015-2020)
- 11.2 Metabolic Disorder Therapeutics Key Players in India (2019-2020)
- 11.3 India Metabolic Disorder Therapeutics Market Size by Type (2015-2020)
- 11.4 India Metabolic Disorder Therapeutics Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

- 12.1 Central & South America Metabolic Disorder Therapeutics Market Size (2015-2020)
- 12.2 Metabolic Disorder Therapeutics Key Players in Central & South America (2019-2020)
- 12.3 Central & South America Metabolic Disorder Therapeutics Market Size by Type (2015-2020)
- 12.4 Central & South America Metabolic Disorder Therapeutics Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

- 13.1 Novo Nordisk A/S
 - 13.1.1 Novo Nordisk A/S Company Details
 - 13.1.2 Novo Nordisk A/S Business Overview and Its Total Revenue
 - 13.1.3 Novo Nordisk A/S Metabolic Disorder Therapeutics Introduction
 - 13.1.4 Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
 - 13.1.5 Novo Nordisk A/S Recent Development
- 13.2 Sanofi S.A.
 - 13.2.1 Sanofi S.A. Company Details
 - 13.2.2 Sanofi S.A. Business Overview and Its Total Revenue
 - 13.2.3 Sanofi S.A. Metabolic Disorder Therapeutics Introduction
 - 13.2.4 Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
 - 13.2.5 Sanofi S.A. Recent Development
- 13.3 Boehringer Ingelheim GmbH

- 13.3.1 Boehringer Ingelheim GmbH Company Details
- 13.3.2 Boehringer Ingelheim GmbH Business Overview and Its Total Revenue
- 13.3.3 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Introduction
- 13.3.4 Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
- 13.3.5 Boehringer Ingelheim GmbH Recent Development
- 13.4 Eli Lilly and Company
 - 13.4.1 Eli Lilly and Company Company Details
 - 13.4.2 Eli Lilly and Company Business Overview and Its Total Revenue
 - 13.4.3 Eli Lilly and Company Metabolic Disorder Therapeutics Introduction
 - 13.4.4 Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
 - 13.4.5 Eli Lilly and Company Recent Development
- 13.5 Merck KgaA
 - 13.5.1 Merck KgaA Company Details
 - 13.5.2 Merck KgaA Business Overview and Its Total Revenue
 - 13.5.3 Merck KgaA Metabolic Disorder Therapeutics Introduction
 - 13.5.4 Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
 - 13.5.5 Merck KgaA Recent Development
- 13.6 Amgen, Inc.
 - 13.6.1 Amgen, Inc. Company Details
 - 13.6.2 Amgen, Inc. Business Overview and Its Total Revenue
 - 13.6.3 Amgen, Inc. Metabolic Disorder Therapeutics Introduction
 - 13.6.4 Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
 - 13.6.5 Amgen, Inc. Recent Development
- 13.7 AstraZeneca PLC
 - 13.7.1 AstraZeneca PLC Company Details
 - 13.7.2 AstraZeneca PLC Business Overview and Its Total Revenue
 - 13.7.3 AstraZeneca PLC Metabolic Disorder Therapeutics Introduction
 - 13.7.4 AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
 - 13.7.5 AstraZeneca PLC Recent Development
- 13.8 Actelion Pharmaceuticals Ltd.
 - 13.8.1 Actelion Pharmaceuticals Ltd. Company Details
 - 13.8.2 Actelion Pharmaceuticals Ltd. Business Overview and Its Total Revenue
 - 13.8.3 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Introduction
 - 13.8.4 Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics

Business (2015-2020)**13.8.5 Actelion Pharmaceuticals Ltd. Recent Development****13.9 Shire PLC****13.9.1 Shire PLC Company Details****13.9.2 Shire PLC Business Overview and Its Total Revenue****13.9.3 Shire PLC Metabolic Disorder Therapeutics Introduction****13.9.4 Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2015-2020)****13.9.5 Shire PLC Recent Development****13.10 AbbVie, Inc.****13.10.1 AbbVie, Inc. Company Details****13.10.2 AbbVie, Inc. Business Overview and Its Total Revenue****13.10.3 AbbVie, Inc. Metabolic Disorder Therapeutics Introduction****13.10.4 AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business****(2015-2020)****13.10.5 AbbVie, Inc. Recent Development****13.11 Biocon Ltd.****10.11.1 Biocon Ltd. Company Details****10.11.2 Biocon Ltd. Business Overview and Its Total Revenue****10.11.3 Biocon Ltd. Metabolic Disorder Therapeutics Introduction****10.11.4 Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business****(2015-2020)****10.11.5 Biocon Ltd. Recent Development****13.12 BioMarin Pharmaceutical, Inc.****10.12.1 BioMarin Pharmaceutical, Inc. Company Details****10.12.2 BioMarin Pharmaceutical, Inc. Business Overview and Its Total Revenue****10.12.3 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Introduction****10.12.4 BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics****Business (2015-2020)****10.12.5 BioMarin Pharmaceutical, Inc. Recent Development****13.13 Bristol-Myers Squibb Company****10.13.1 Bristol-Myers Squibb Company Company Details****10.13.2 Bristol-Myers Squibb Company Business Overview and Its Total Revenue****10.13.3 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Introduction****10.13.4 Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics****Business (2015-2020)****10.13.5 Bristol-Myers Squibb Company Recent Development****13.14 Cipla, Inc.****10.14.1 Cipla, Inc. Company Details****10.14.2 Cipla, Inc. Business Overview and Its Total Revenue**

10.14.3 Cipla, Inc. Metabolic Disorder Therapeutics Introduction

10.14.4 Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020)

10.14.5 Cipla, Inc. Recent Development

13.15 CymaBay Therapeutics, Inc.

10.15.1 CymaBay Therapeutics, Inc. Company Details

10.15.2 CymaBay Therapeutics, Inc. Business Overview and Its Total Revenue

10.15.3 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Introduction

10.15.4 CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020)

10.15.5 CymaBay Therapeutics, Inc. Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Disclaimer

15.3 Author Details

List Of Tables

LIST OF TABLES

- Table 1. Metabolic Disorder Therapeutics Key Market Segments
- Table 2. Key Players Covered: Ranking by Metabolic Disorder Therapeutics Revenue
- Table 3. Ranking of Global Top Metabolic Disorder Therapeutics Manufacturers by Revenue (US\$ Million) in 2019
- Table 4. Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026
- Table 5. Key Players of Lysosomal Storage Diseases
- Table 6. Key Players of Diabetes
- Table 7. Key Players of Obesity
- Table 8. Key Players of Inherited Metabolic Disorders
- Table 9. Key Players of Hypercholesterolemia
- Table 10. COVID-19 Impact Global Market: (Four Metabolic Disorder Therapeutics Market Size Forecast Scenarios)
- Table 11. Opportunities and Trends for Metabolic Disorder Therapeutics Players in the COVID-19 Landscape
- Table 12. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
- Table 13. Key Regions/Countries Measures against Covid-19 Impact
- Table 14. Proposal for Metabolic Disorder Therapeutics Players to Combat Covid-19 Impact
- Table 15. Global Metabolic Disorder Therapeutics Market Size Growth by Application (US\$ Million): 2020 VS 2026
- Table 16. Global Metabolic Disorder Therapeutics Market Size by Regions (US\$ Million): 2020 VS 2026
- Table 17. Global Metabolic Disorder Therapeutics Market Size by Regions (2015-2020) (US\$ Million)
- Table 18. Global Metabolic Disorder Therapeutics Market Share by Regions (2015-2020)
- Table 19. Global Metabolic Disorder Therapeutics Forecasted Market Size by Regions (2021-2026) (US\$ Million)
- Table 20. Global Metabolic Disorder Therapeutics Market Share by Regions (2021-2026)
- Table 21. Market Top Trends
- Table 22. Key Drivers: Impact Analysis
- Table 23. Key Challenges
- Table 24. Metabolic Disorder Therapeutics Market Growth Strategy

Table 25. Main Points Interviewed from Key Metabolic Disorder Therapeutics Players

Table 26. Global Metabolic Disorder Therapeutics Revenue by Players (2015-2020)
(Million US\$)

Table 27. Global Metabolic Disorder Therapeutics Market Share by Players (2015-2020)

Table 28. Global Top Metabolic Disorder Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metabolic Disorder Therapeutics as of 2019)

Table 29. Global Metabolic Disorder Therapeutics by Players Market Concentration Ratio (CR5 and HHI)

Table 30. Key Players Headquarters and Area Served

Table 31. Key Players Metabolic Disorder Therapeutics Product Solution and Service

Table 32. Date of Enter into Metabolic Disorder Therapeutics Market

Table 33. Mergers & Acquisitions, Expansion Plans

Table 34. Global Metabolic Disorder Therapeutics Market Size by Type (2015-2020)
(Million US\$)

Table 35. Global Metabolic Disorder Therapeutics Market Size Share by Type
(2015-2020)

Table 36. Global Metabolic Disorder Therapeutics Revenue Market Share by Type
(2021-2026)

Table 37. Global Metabolic Disorder Therapeutics Market Size Share by Application
(2015-2020)

Table 38. Global Metabolic Disorder Therapeutics Market Size by Application
(2015-2020) (Million US\$)

Table 39. Global Metabolic Disorder Therapeutics Market Size Share by Application
(2021-2026)

Table 40. North America Key Players Metabolic Disorder Therapeutics Revenue
(2019-2020) (Million US\$)

Table 41. North America Key Players Metabolic Disorder Therapeutics Market Share
(2019-2020)

Table 42. North America Metabolic Disorder Therapeutics Market Size by Type
(2015-2020) (Million US\$)

Table 43. North America Metabolic Disorder Therapeutics Market Share by Type
(2015-2020)

Table 44. North America Metabolic Disorder Therapeutics Market Size by Application
(2015-2020) (Million US\$)

Table 45. North America Metabolic Disorder Therapeutics Market Share by Application
(2015-2020)

Table 46. Europe Key Players Metabolic Disorder Therapeutics Revenue (2019-2020)
(Million US\$)

Table 47. Europe Key Players Metabolic Disorder Therapeutics Market Share (2019-2020)

Table 48. Europe Metabolic Disorder Therapeutics Market Size by Type (2015-2020) (Million US\$)

Table 49. Europe Metabolic Disorder Therapeutics Market Share by Type (2015-2020)

Table 50. Europe Metabolic Disorder Therapeutics Market Size by Application (2015-2020) (Million US\$)

Table 51. Europe Metabolic Disorder Therapeutics Market Share by Application (2015-2020)

Table 52. China Key Players Metabolic Disorder Therapeutics Revenue (2019-2020) (Million US\$)

Table 53. China Key Players Metabolic Disorder Therapeutics Market Share (2019-2020)

Table 54. China Metabolic Disorder Therapeutics Market Size by Type (2015-2020) (Million US\$)

Table 55. China Metabolic Disorder Therapeutics Market Share by Type (2015-2020)

Table 56. China Metabolic Disorder Therapeutics Market Size by Application (2015-2020) (Million US\$)

Table 57. China Metabolic Disorder Therapeutics Market Share by Application (2015-2020)

Table 58. Japan Key Players Metabolic Disorder Therapeutics Revenue (2019-2020) (Million US\$)

Table 59. Japan Key Players Metabolic Disorder Therapeutics Market Share (2019-2020)

Table 60. Japan Metabolic Disorder Therapeutics Market Size by Type (2015-2020) (Million US\$)

Table 61. Japan Metabolic Disorder Therapeutics Market Share by Type (2015-2020)

Table 62. Japan Metabolic Disorder Therapeutics Market Size by Application (2015-2020) (Million US\$)

Table 63. Japan Metabolic Disorder Therapeutics Market Share by Application (2015-2020)

Table 64. Southeast Asia Key Players Metabolic Disorder Therapeutics Revenue (2019-2020) (Million US\$)

Table 65. Southeast Asia Key Players Metabolic Disorder Therapeutics Market Share (2019-2020)

Table 66. Southeast Asia Metabolic Disorder Therapeutics Market Size by Type (2015-2020) (Million US\$)

Table 67. Southeast Asia Metabolic Disorder Therapeutics Market Share by Type (2015-2020)

Table 68. Southeast Asia Metabolic Disorder Therapeutics Market Size by Application (2015-2020) (Million US\$)

Table 69. Southeast Asia Metabolic Disorder Therapeutics Market Share by Application (2015-2020)

Table 70. India Key Players Metabolic Disorder Therapeutics Revenue (2019-2020) (Million US\$)

Table 71. India Key Players Metabolic Disorder Therapeutics Market Share (2019-2020)

Table 72. India Metabolic Disorder Therapeutics Market Size by Type (2015-2020) (Million US\$)

Table 73. India Metabolic Disorder Therapeutics Market Share by Type (2015-2020)

Table 74. India Metabolic Disorder Therapeutics Market Size by Application (2015-2020) (Million US\$)

Table 75. India Metabolic Disorder Therapeutics Market Share by Application (2015-2020)

Table 76. Central & South America Key Players Metabolic Disorder Therapeutics Revenue (2019-2020) (Million US\$)

Table 77. Central & South America Key Players Metabolic Disorder Therapeutics Market Share (2019-2020)

Table 78. Central & South America Metabolic Disorder Therapeutics Market Size by Type (2015-2020) (Million US\$)

Table 79. Central & South America Metabolic Disorder Therapeutics Market Share by Type (2015-2020)

Table 80. Central & South America Metabolic Disorder Therapeutics Market Size by Application (2015-2020) (Million US\$)

Table 81. Central & South America Metabolic Disorder Therapeutics Market Share by Application (2015-2020)

Table 82. Novo Nordisk A/S Company Details

Table 83. Novo Nordisk A/S Business Overview

Table 84. Novo Nordisk A/S Product

Table 85. Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US\$)

Table 86. Novo Nordisk A/S Recent Development

Table 87. Sanofi S.A. Company Details

Table 88. Sanofi S.A. Business Overview

Table 89. Sanofi S.A. Product

Table 90. Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US\$)

Table 91. Sanofi S.A. Recent Development

Table 92. Boehringer Ingelheim GmbH Company Details

- Table 93. Boehringer Ingelheim GmbH Business Overview
- Table 94. Boehringer Ingelheim GmbH Product
- Table 95. Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US\$)
- Table 96. Boehringer Ingelheim GmbH Recent Development
- Table 97. Eli Lilly and Company Company Details
- Table 98. Eli Lilly and Company Business Overview
- Table 99. Eli Lilly and Company Product
- Table 100. Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US\$)
- Table 101. Eli Lilly and Company Recent Development
- Table 102. Merck KgaA Company Details
- Table 103. Merck KgaA Business Overview
- Table 104. Merck KgaA Product
- Table 105. Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US\$)
- Table 106. Merck KgaA Recent Development
- Table 107. Amgen, Inc. Company Details
- Table 108. Amgen, Inc. Business Overview
- Table 109. Amgen, Inc. Product
- Table 110. Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US\$)
- Table 111. Amgen, Inc. Recent Development
- Table 112. AstraZeneca PLC Company Details
- Table 113. AstraZeneca PLC Business Overview
- Table 114. AstraZeneca PLC Product
- Table 115. AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US\$)
- Table 116. AstraZeneca PLC Recent Development
- Table 117. Actelion Pharmaceuticals Ltd. Business Overview
- Table 118. Actelion Pharmaceuticals Ltd. Product
- Table 119. Actelion Pharmaceuticals Ltd. Company Details
- Table 120. Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US\$)
- Table 121. Actelion Pharmaceuticals Ltd. Recent Development
- Table 122. Shire PLC Company Details
- Table 123. Shire PLC Business Overview
- Table 124. Shire PLC Product
- Table 125. Shire PLC Revenue in Metabolic Disorder Therapeutics Business

(2015-2020) (Million US\$)

Table 126. Shire PLC Recent Development

Table 127. AbbVie, Inc. Company Details

Table 128. AbbVie, Inc. Business Overview

Table 129. AbbVie, Inc. Product

Table 130. AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business

(2015-2020) (Million US\$)

Table 131. AbbVie, Inc. Recent Development

Table 132. Biocon Ltd. Company Details

Table 133. Biocon Ltd. Business Overview

Table 134. Biocon Ltd. Product

Table 135. Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business

(2015-2020) (Million US\$)

Table 136. Biocon Ltd. Recent Development

Table 137. BioMarin Pharmaceutical, Inc. Company Details

Table 138. BioMarin Pharmaceutical, Inc. Business Overview

Table 139. BioMarin Pharmaceutical, Inc. Product

Table 140. BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics

Business (2015-2020) (Million US\$)

Table 141. BioMarin Pharmaceutical, Inc. Recent Development

Table 142. Bristol-Myers Squibb Company Company Details

Table 143. Bristol-Myers Squibb Company Business Overview

Table 144. Bristol-Myers Squibb Company Product

Table 145. Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics

Business (2015-2020) (Million US\$)

Table 146. Bristol-Myers Squibb Company Recent Development

Table 147. Cipla, Inc. Company Details

Table 148. Cipla, Inc. Business Overview

Table 149. Cipla, Inc. Product

Table 150. Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business

(2015-2020) (Million US\$)

Table 151. Cipla, Inc. Recent Development

Table 152. CymaBay Therapeutics, Inc. Company Details

Table 153. CymaBay Therapeutics, Inc. Business Overview

Table 154. CymaBay Therapeutics, Inc. Product

Table 155. CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics

Business (2015-2020) (Million US\$)

Table 156. CymaBay Therapeutics, Inc. Recent Development

Table 157. Research Programs/Design for This Report

Table 158. Key Data Information from Secondary Sources

Table 159. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Metabolic Disorder Therapeutics Market Share by Type: 2020 VS 2026

Figure 2. Lysosomal Storage Diseases Features

Figure 3. Diabetes Features

Figure 4. Obesity Features

Figure 5. Inherited Metabolic Disorders Features

Figure 6. Hypercholesterolemia Features

Figure 7. Global Metabolic Disorder Therapeutics Market Share by Application: 2020 VS 2026

Figure 8. Oral Case Studies

Figure 9. Parenteral Case Studies

Figure 10. Others Case Studies

Figure 11. Metabolic Disorder Therapeutics Report Years Considered

Figure 12. Global Metabolic Disorder Therapeutics Market Size YoY Growth 2015-2026 (US\$ Million)

Figure 13. Global Metabolic Disorder Therapeutics Market Share by Regions: 2020 VS 2026

Figure 14. Global Metabolic Disorder Therapeutics Market Share by Regions (2021-2026)

Figure 15. Porter's Five Forces Analysis

Figure 16. Global Metabolic Disorder Therapeutics Market Share by Players in 2019

Figure 17. Global Top Metabolic Disorder Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metabolic Disorder Therapeutics as of 2019)

Figure 18. The Top 10 and 5 Players Market Share by Metabolic Disorder Therapeutics Revenue in 2019

Figure 19. North America Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2020) (Million US\$)

Figure 20. Europe Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2020) (Million US\$)

Figure 21. China Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2020) (Million US\$)

Figure 22. Japan Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2020) (Million US\$)

Figure 23. Southeast Asia Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2020) (Million US\$)

Figure 24. India Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2020) (Million US\$)

Figure 25. Central & South America Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2020) (Million US\$)

Figure 26. Novo Nordisk A/S Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 27. Novo Nordisk A/S Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)

Figure 28. Sanofi S.A. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 29. Sanofi S.A. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)

Figure 30. Boehringer Ingelheim GmbH Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 31. Boehringer Ingelheim GmbH Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)

Figure 32. Eli Lilly and Company Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 33. Eli Lilly and Company Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)

Figure 34. Merck KgaA Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 35. Merck KgaA Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)

Figure 36. Amgen, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 37. Amgen, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)

Figure 38. AstraZeneca PLC Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 39. AstraZeneca PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)

Figure 40. Actelion Pharmaceuticals Ltd. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 41. Actelion Pharmaceuticals Ltd. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)

Figure 42. Shire PLC Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 43. Shire PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)

Figure 44. AbbVie, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 45. AbbVie, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)

Figure 46. Biocon Ltd. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 47. Biocon Ltd. Revenue Growth Rate in Metabolic Disorder Therapeutics

Business (2015-2020)

Figure 48. BioMarin Pharmaceutical, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 49. BioMarin Pharmaceutical, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)

Figure 50. Bristol-Myers Squibb Company Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 51. Bristol-Myers Squibb Company Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)

Figure 52. Cipla, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 53. Cipla, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)

Figure 54. CymaBay Therapeutics, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 55. CymaBay Therapeutics, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)

Figure 56. Bottom-up and Top-down Approaches for This Report

Figure 57. Data Triangulation

Figure 58. Key Executives Interviewed

I would like to order

Product name: Covid-19 Impact on Global Metabolic Disorder Therapeutics Market Size, Status and Forecast 2020-2026

Product link: <https://marketpublishers.com/r/C4EC4E751BEFEN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C4EC4E751BEFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

